These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7888109)

  • 1. PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.
    Emmerling MR; Gregor VE; Schwarz RD; Scholten JD; Callahan MJ; Lee C; Moore CJ; Raby C; Lipinski WJ; Davis RE
    Mol Neurobiol; 1994; 9(1-3):93-106. PubMed ID: 7888109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization.
    Schwarz RD; Callahan MJ; Coughenour LL; Dickerson MR; Kinsora JJ; Lipinski WJ; Raby CA; Spencer CJ; Tecle H
    J Pharmacol Exp Ther; 1999 Nov; 291(2):812-22. PubMed ID: 10525104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of methoctramine-related polyamines as muscarinic antagonist: effect of replacing the inner polymethylene chain with cyclic moieties.
    Tumiatti V; Minarini A; Milelli A; Rosini M; Buccioni M; Marucci G; Ghelardini C; Bellucci C; Melchiorre C
    Bioorg Med Chem; 2007 Mar; 15(6):2312-21. PubMed ID: 17276075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic modulations of neuronal anticholinesterase responses.
    Salmon A; Erb C; Meshorer E; Ginzberg D; Adani Y; Rabinovitz I; Amitai G; Soreq H
    Chem Biol Interact; 2005 Dec; 157-158():105-13. PubMed ID: 16289123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.
    Jaen J; Barrett S; Brann M; Callahan M; Davis R; Doyle P; Eubanks D; Lauffer D; Lauffer L; Lipinski W
    Life Sci; 1995; 56(11-12):845-52. PubMed ID: 10188784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals.
    Carey GJ; Billard W; Binch H; Cohen-Williams M; Crosby G; Grzelak M; Guzik H; Kozlowski JA; Lowe DB; Pond AJ; Tedesco RP; Watkins RW; Coffin VL
    Eur J Pharmacol; 2001 Nov; 431(2):189-200. PubMed ID: 11728425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease.
    Sedman AJ; Bockbrader H; Schwarz RD
    Life Sci; 1995; 56(11-12):877-82. PubMed ID: 10188788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
    Cheng K; Khurana S; Chen Y; Kennedy RH; Zimniak P; Raufman JP
    J Pharmacol Exp Ther; 2002 Oct; 303(1):29-35. PubMed ID: 12235229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects of organophosphorus anticholinesterases on muscarinic receptor-mediated inhibition of acetylcholine release in rat striatum.
    Liu J; Chakraborti T; Pope C
    Toxicol Appl Pharmacol; 2002 Jan; 178(2):102-8. PubMed ID: 11814330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys.
    Lange HS; Cannon CE; Drott JT; Kuduk SD; Uslaner JM
    J Pharmacol Exp Ther; 2015 Dec; 355(3):442-50. PubMed ID: 26446308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
    Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
    J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors.
    Skaddan MB; Kilbourn MR; Snyder SE; Sherman PS
    J Cereb Blood Flow Metab; 2001 Feb; 21(2):144-8. PubMed ID: 11176279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis.
    Tsukada H; Nishiyama S; Fukumoto D; Ohba H; Sato K; Kakiuchi T
    Synapse; 2004 Apr; 52(1):1-10. PubMed ID: 14755627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the anticholinesterase activity of a series of organophosphates with their ability to compete with agonist binding to muscarinic receptors.
    Ward TR; Ferris DJ; Tilson HA; Mundy WR
    Toxicol Appl Pharmacol; 1993 Oct; 122(2):300-7. PubMed ID: 8212012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists.
    Lainé DI; Wan Z; Yan H; Zhu C; Xie H; Fu W; Busch-Petersen J; Neipp C; Davis R; Widdowson KL; Blaney FE; Foley J; Bacon AM; Webb EF; Luttmann MA; Burman M; Sarau HM; Salmon M; Palovich MR; Belmonte K
    J Med Chem; 2009 Aug; 52(16):5241-52. PubMed ID: 19630384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride.
    Matsunaga Y; Tanaka T; Yoshinaga K; Ueki S; Hori Y; Eta R; Kawabata Y; Yoshii K; Yoshida K; Matsumura T; Furuta S; Takei M; Tack J; Itoh Z
    J Pharmacol Exp Ther; 2011 Mar; 336(3):791-800. PubMed ID: 21123674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical to Human Translational Pharmacology of the Novel M
    Uslaner JM; Kuduk SD; Wittmann M; Lange HS; Fox SV; Min C; Pajkovic N; Harris D; Cilissen C; Mahon C; Mostoller K; Warrington S; Beshore DC
    J Pharmacol Exp Ther; 2018 Jun; 365(3):556-566. PubMed ID: 29563325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
    Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near-complete adaptation of the PRiMA knockout to the lack of central acetylcholinesterase.
    Farar V; Mohr F; Legrand M; Lamotte d'Incamps B; Cendelin J; Leroy J; Abitbol M; Bernard V; Baud F; Fournet V; Houze P; Klein J; Plaud B; Tuma J; Zimmermann M; Ascher P; Hrabovska A; Myslivecek J; Krejci E
    J Neurochem; 2012 Sep; 122(5):1065-80. PubMed ID: 22747514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.
    Buccafusco JJ; Terry AV; Webster SJ; Martin D; Hohnadel EJ; Bouchard KA; Warner SE
    Psychopharmacology (Berl); 2008 Aug; 199(3):481-94. PubMed ID: 17657478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.